Equities

Biotron Ltd

Biotron Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)0.02
  • Today's Change-0.001 / -4.76%
  • Shares traded857.44k
  • 1 Year change-41.18%
  • Beta0.1264
Data delayed at least 20 minutes, as of Sep 20 2024 07:10 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in AUDIncome statement in AUDView more

Year on year Biotron Ltd grew revenues 14.94% from 1.43m to 1.65m while net income improved from a loss of 3.49m to a smaller loss of 3.44m.
Gross margin-120.34%
Net profit margin-208.89%
Operating margin-213.12%
Return on assets-148.49%
Return on equity-234.69%
Return on investment-234.15%
More ▼

Cash flow in AUDView more

In 2024, cash reserves at Biotron Ltd fell by 3.59m. However, Cash Flow from Investing was flat, indicating that little new money was committed to growth. In addition the company used 3.57m for operations while cash used for financing totalled 22.62k.
Cash flow per share-0.0038
Price/Cash flow per share--
Book value per share-0.0003
Tangible book value per share-0.0003
More ▼

Balance sheet in AUDView more

Biotron Ltd uses little or no debt in its capital structure.
Current ratio0.5787
Quick ratio--
Total debt/total equity--
Total debt/total capital--
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.